Skip to main content

Drug Interactions between Tivicay and Viramune

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

nevirapine dolutegravir

Applies to: Viramune (nevirapine) and Tivicay (dolutegravir)

GENERALLY AVOID: Coadministration with nevirapine may theoretically decrease the plasma concentrations of dolutegravir. The interaction has not been specifically studied. However, dolutegravir is partially metabolized by CYP450 3A4, and nevirapine is a known inducer of the isoenzyme. Coadministration with other CYP450 3A4 inducers such as efavirenz, etravirine, rifampin, and tipranavir/ritonavir have been found to significantly reduce dolutegravir systemic exposure (AUC) by over 50% and trough plasma concentration (Cmin; 24 hours postdose) by approximately 75% or more.

MANAGEMENT: Coadministration of dolutegravir with nevirapine should be avoided because there are insufficient data to make dosing recommendations.

References

  1. (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare
  2. (2014) "Product Information. Triumeq (abacavir/dolutegravir/lamivudine)." ViiV Healthcare
  3. (2019) "Product Information. Dovato (dolutegravir-lamivudine)." ViiV Healthcare

Switch to consumer interaction data

Drug and food interactions

Minor

dolutegravir food

Applies to: Tivicay (dolutegravir)

Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.

References

  1. (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer